MQS Management LLC Takes $619,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

MQS Management LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,513 shares of the medical research company's stock, valued at approximately $619,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares during the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after buying an additional 712,958 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after buying an additional 77,981 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in IQVIA by 2.5% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after purchasing an additional 59,426 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

Shares of IQV stock traded down $2.80 during trading on Friday, hitting $162.73. The company had a trading volume of 1,156,699 shares, compared to its average volume of 1,660,352. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The stock's 50-day moving average is $151.96 and its two-hundred day moving average is $171.98. The stock has a market capitalization of $28.15 billion, a price-to-earnings ratio of 22.17, a price-to-earnings-growth ratio of 1.81 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. During the same period last year, the business earned $2.54 earnings per share. The business's quarterly revenue was up 2.5% on a year-over-year basis. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. UBS Group dropped their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Mizuho dropped their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a report on Thursday, May 15th. Truist Financial dropped their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday, April 10th. Finally, Redburn Partners set a $188.00 price objective on shares of IQVIA in a report on Friday, May 23rd. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $222.45.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.